CY1105878T1 - Βελτιωμενο συστημα διαδepμικης χορηγησης - Google Patents

Βελτιωμενο συστημα διαδepμικης χορηγησης

Info

Publication number
CY1105878T1
CY1105878T1 CY20061101845T CY061101845T CY1105878T1 CY 1105878 T1 CY1105878 T1 CY 1105878T1 CY 20061101845 T CY20061101845 T CY 20061101845T CY 061101845 T CY061101845 T CY 061101845T CY 1105878 T1 CY1105878 T1 CY 1105878T1
Authority
CY
Cyprus
Prior art keywords
amino
drug
matrix
functional drug
tds
Prior art date
Application number
CY20061101845T
Other languages
English (en)
Inventor
Mike Hannay
Dietrich Wilhelm Schacht
Hans-Michael Wolff
Original Assignee
Schwarz Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schwarz Pharma Ag filed Critical Schwarz Pharma Ag
Publication of CY1105878T1 publication Critical patent/CY1105878T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Παρέχεται ένα βελτιωμένο Σύστημα Διαδερμικής Χορήγησης (TDS) που περιλαμβάνει ένα υπόστρωμα αδρανές στα συστατικά της μήτρας, μία αυτοκόλλητη μήτρα που περιέχει ένα αμινολειτουργικό φάρμακο και ένα προστατευτικό έλασμα ή φύλλο προς αφαίρεση πριν τη χρήση, χαρακτηριζόμενο από το ότι η αυτοκόλλητη μήτρα αποτελείται από ένα στερεό ή ημι-στερεό ημί-διαπερατό πολυμερές (1) στην οποία έχει ενσωματωθεί ένα αμινολειτουργικό φάρμακο στη μορφή ελεύθερης βάσης του, (2) η οποία είναι κορεσμένη με το αμινο-λειτουργικό φάρμακο και περιέχει το προαναφερόμενο φάρμακο ως μία πολλαπλότητα μικροαποθηκών μέσα στη μήτρα, (3) η οποία είναι υψηλά διαπερατή από την ελεύθερη βάση του αμινο-λειτουργικού φαρμάκου, (4) η οποία είναι αδιαπέραστη από την πρωτονιομένη μορφή του αμινολειτουργικού φαρμάκου, (5) στην οποία η μέγιστη διάμετρος των μικροαποθηκών είναι μικρότερη από το πάχος της μήτρας. Το προαναφερόμενο TDS παρέχει ενισχυμένη ροή του αμινολειτουργικού φαρμάκου διαμέσου της διεπαφής TDS/δέρματος.
CY20061101845T 2002-07-30 2006-12-21 Βελτιωμενο συστημα διαδepμικης χορηγησης CY1105878T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02016864A EP1386604A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system
EP03766330A EP1524971B1 (en) 2002-07-30 2003-07-28 Improved transdermal delivery system
PCT/EP2003/008319 WO2004012719A1 (en) 2002-07-30 2003-07-28 Improved transdermal delivery system

Publications (1)

Publication Number Publication Date
CY1105878T1 true CY1105878T1 (el) 2011-02-02

Family

ID=30011092

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101845T CY1105878T1 (el) 2002-07-30 2006-12-21 Βελτιωμενο συστημα διαδepμικης χορηγησης

Country Status (22)

Country Link
EP (2) EP1386604A1 (el)
JP (1) JP4837915B2 (el)
KR (1) KR101016914B1 (el)
CN (1) CN100558350C (el)
AT (1) ATE343380T1 (el)
AU (1) AU2003266252B2 (el)
BR (1) BR0313092A (el)
CA (1) CA2490573C (el)
CY (1) CY1105878T1 (el)
DE (1) DE60309329T2 (el)
DK (1) DK1524971T3 (el)
ES (1) ES2273042T3 (el)
HK (1) HK1083458A1 (el)
IL (1) IL165917A (el)
MX (1) MXPA05000349A (el)
NO (1) NO334187B1 (el)
NZ (1) NZ537476A (el)
PL (1) PL376999A1 (el)
PT (1) PT1524971E (el)
SI (1) SI1524971T1 (el)
WO (1) WO2004012719A1 (el)
ZA (1) ZA200500255B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
US9155725B2 (en) 2008-02-27 2015-10-13 Hisamitsu Pharmaceutical Co., Inc. Adhesive skin patch and packaged product
WO2009107477A1 (ja) * 2008-02-27 2009-09-03 久光製薬株式会社 貼付製剤
HUE039447T2 (hu) * 2009-12-22 2018-12-28 Ucb Biopharma Sprl Polivinilpirrolidon rotigotin nem kristályos formája szilárd diszperziójának stabilizálására
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
BR112015032929B1 (pt) 2013-07-03 2022-08-23 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico
WO2015177212A1 (en) * 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
ES2924899T3 (es) 2014-05-20 2022-10-11 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que contiene rotigotina
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
DK3854388T3 (da) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof
EP3949956A1 (en) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
IT1311696B1 (it) * 1999-06-22 2002-03-19 Zanussi Elettromecc Compressore del fluido frigorigeno azionato da un motore elettricoa frequenza di alimentazione variabile
JP2002045699A (ja) * 2000-08-08 2002-02-12 Mitsubishi Electric Corp 排ガス浄化用層状電気化学触媒
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
NZ528148A (en) * 2001-03-16 2006-02-24 Alza Corp Transdermal patch for administering fentanyl
NZ527930A (en) * 2001-03-16 2005-11-25 Andrx Pharmaceuticals Llc Controlled release sulfonylurea formulation
ATE246919T1 (de) * 2001-05-08 2003-08-15 Sanol Arznei Schwarz Gmbh Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine

Also Published As

Publication number Publication date
DE60309329D1 (de) 2006-12-07
CN1671365A (zh) 2005-09-21
EP1386604A1 (en) 2004-02-04
SI1524971T1 (sl) 2007-02-28
AU2003266252A1 (en) 2004-02-23
IL165917A (en) 2007-07-24
EP1524971A1 (en) 2005-04-27
NZ537476A (en) 2007-08-31
HK1083458A1 (en) 2006-07-07
JP2005535686A (ja) 2005-11-24
IL165917A0 (en) 2006-01-15
ES2273042T3 (es) 2007-05-01
CA2490573C (en) 2011-06-07
PT1524971E (pt) 2007-01-31
DE60309329T2 (de) 2008-04-17
NO334187B1 (no) 2014-01-13
KR20050025638A (ko) 2005-03-14
PL376999A1 (pl) 2006-01-23
ATE343380T1 (de) 2006-11-15
AU2003266252B2 (en) 2008-11-20
MXPA05000349A (es) 2005-03-31
CN100558350C (zh) 2009-11-11
JP4837915B2 (ja) 2011-12-14
NO20050770L (no) 2005-02-11
KR101016914B1 (ko) 2011-02-22
ZA200500255B (en) 2006-01-25
EP1524971B1 (en) 2006-10-25
BR0313092A (pt) 2005-06-21
CA2490573A1 (en) 2004-02-12
DK1524971T3 (da) 2007-02-19
WO2004012719A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
CY1105878T1 (el) Βελτιωμενο συστημα διαδepμικης χορηγησης
NO20050472L (no) Forbedret transdermalt leveringssystem for administrering av rotigotin
CY1113997T1 (el) Διαδερμικο θεραπευτικο συστημα με μια επικολλουμενη στρωση, μεθοδος για την σιλικονοποιηση μιας οπισθιας στρωσης και χρηση της οπισθιας στρωσης
CY1108250T1 (el) Διαδερμικο θεραπευτικο συστημα για τη χορηγηση μη στεροειδικων αντιφλογιστικων που φερουν καρβοξυλομαδες, καθως και μεθοδος για την παραγωγη του
CY1106744T1 (el) Θεραπευτικο αυτοκολλητο διαδερμικο συστημα με φορεα πολυσιλοξανης που περιλαμβανει καψαϊκινη
AR097045A2 (es) Sistema terapéutico transdérmico
CY1106811T1 (el) Διαδερμικη γρανισετρονη
TW570815B (en) Transdermal therapeutic system (TTS) containing the active substance fentanyl
CY1116638T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας
DK1009393T3 (da) Transdermalt, terapeutisk system med hæfteklæbende reservoirlag og bagsidelag, som er elastisk i én retning
ES2167116T3 (es) Sistema terapeutico transdermico (tts) que contiene pergolida.
RU2016109449A (ru) Устройства для трансдермальной доставки дексмедетомидина и способы их применения
CY1109229T1 (el) Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο
MX2019007389A (es) Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno.
AR043248A1 (es) Sistema terapeutico transdermico estable a los rayos uv
DK0474647T3 (da) Fremgangsmåde og indretning til frigivelse af lægemidler til huden
DK1706133T3 (da) Fremgangsmåder til beskyttelse mod stråling ved anvendelse af flagellin
DK1143938T3 (da) Transdermalt terapeutisk system med en selvklæbende matrix, der indeholder organiske syreadditionssalte af alkaloider af morphin- eller morphin-type
WO2016149077A3 (en) Fentanyl transdermal delivery system
DK0379933T3 (da) Superficielt behandlingssystem med indhold af et antineoplastisk aktivstof, især 5-fluoruracil
ZA200509384B (en) Method and device for improving the permeability of the human skin
DE60315280D1 (de) Transdermale pflaster mit einer adhäsiven siliconmatrix stabilisiert mit methacryl copolymeren
ATE485817T1 (de) Pflaster, enthaltend fentanylum